论文部分内容阅读
目的观察重组人-α2b干扰素(rhIFN-α2b)含片对体外、体内的抗病毒作用,为临床用药提供药理学依据。方法采用体外和体内抗病毒试验。结果rhIFN-α2b含片浓度为400~250 000 IU/mL时,对单纯疱疹病毒(HSV-1、HSV-2)和水痘-带状疱疹病毒有明显抑制作用,并在31.2~1 000 IU/mL浓度时,对乙型肝炎病毒也有明显抑制作用。小鼠抗流感病毒试验表明,口含rhIFN-α2b 500~50 000 IU/只,能明显降低动物死亡率,并延长存活时间。结论rhIFN-α2b含片对体内、体外病毒均有明显的抑制作用。
Objective To observe the antiviral effect of recombinant human interferon-α 2b (rhIFN-α2b) tablets in vitro and in vivo, and to provide pharmacological evidence for clinical use. Methods In vitro and in vivo antiviral assays were used. Results When the concentration of rhIFN-α2b was 400-250 000 IU / mL, HSV-1, HSV-2 and varicella-zoster virus were significantly inhibited, and at the dose of 31.2-1 000 IU / mL concentration, the hepatitis B virus also has a significant inhibitory effect. Mouse anti-influenza virus test showed that mouth with rhIFN-α2b 500 ~ 50,000 IU / only, can significantly reduce animal mortality and prolong survival. Conclusion rhIFN-α2b-containing tablet has obvious inhibitory effect on virus in vivo and in vitro.